Economic burden of seasonal influenza in the United States
- PMID: 29801998
- DOI: 10.1016/j.vaccine.2018.05.057
Economic burden of seasonal influenza in the United States
Abstract
Background: Seasonal influenza is responsible for a large disease and economic burden. Despite the expanding recommendation of influenza vaccination, influenza has continued to be a major public health concern in the United States (U.S.). To evaluate influenza prevention strategies it is important that policy makers have current estimates of the economic burden of influenza.
Objective: To provide an updated estimate of the average annual economic burden of seasonal influenza in the U.S. population in the presence of vaccination efforts.
Methods: We evaluated estimates of age-specific influenza-attributable outcomes (ill-non medically attended, office-based outpatient visit, emergency department visits, hospitalizations and death) and associated productivity loss. Health outcome rates were applied to the 2015 U.S. population and multiplied by the relevant estimated unit costs for each outcome. We evaluated both direct healthcare costs and indirect costs (absenteeism from paid employment) reporting results from both a healthcare system and societal perspective. Results were presented in five age groups (<5 years, 5-17 years, 18-49 years, 50-64 years and ≥65 years of age).
Results: The estimated average annual total economic burden of influenza to the healthcare system and society was $11.2 billion ($6.3-$25.3 billion). Direct medical costs were estimated to be $3.2 billion ($1.5-$11.7 billion) and indirect costs $8.0 billion ($4.8-$13.6 billion). These total costs were based on the estimated average numbers of (1) ill-non medically attended patients (21.6 million), (2) office-based outpatient visits (3.7 million), (3) emergency department visit (0.65 million) (4) hospitalizations (247.0 thousand), (5) deaths (36.3 thousand) and (6) days of productivity lost (20.1 million).
Conclusions: This study provides an updated estimate of the total economic burden of influenza in the U.S. Although we found a lower total cost than previously estimated, our results confirm that influenza is responsible for a substantial economic burden in the U.S.
Keywords: Cost-of-illness; Disease burden; Economic burden; Influenza; Productivity.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
The annual impact of seasonal influenza in the US: measuring disease burden and costs.Vaccine. 2007 Jun 28;25(27):5086-96. doi: 10.1016/j.vaccine.2007.03.046. Epub 2007 Apr 20. Vaccine. 2007. PMID: 17544181
-
The Annual Burden of Seasonal Influenza in the US Veterans Affairs Population.PLoS One. 2017 Jan 3;12(1):e0169344. doi: 10.1371/journal.pone.0169344. eCollection 2017. PLoS One. 2017. PMID: 28046080 Free PMC article.
-
Health and economic burden of influenza-associated illness in South Africa, 2013-2015.Influenza Other Respir Viruses. 2019 Sep;13(5):484-495. doi: 10.1111/irv.12650. Epub 2019 Jun 11. Influenza Other Respir Viruses. 2019. PMID: 31187609 Free PMC article.
-
Direct, indirect and intangible costs of acute hand and wrist injuries: A systematic review.Injury. 2016 Dec;47(12):2614-2626. doi: 10.1016/j.injury.2016.09.041. Epub 2016 Oct 1. Injury. 2016. PMID: 27751502 Review.
-
The burden of influenza in children.Curr Opin Infect Dis. 2007 Jun;20(3):259-63. doi: 10.1097/QCO.0b013e3280ad4687. Curr Opin Infect Dis. 2007. PMID: 17471035 Review.
Cited by
-
Evaluating equity-promoting interventions to prevent race-based inequities in influenza outcomes.medRxiv [Preprint]. 2024 Jul 11:2024.05.20.24307635. doi: 10.1101/2024.05.20.24307635. medRxiv. 2024. PMID: 39040204 Free PMC article. Preprint.
-
Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection.NPJ Vaccines. 2024 May 31;9(1):96. doi: 10.1038/s41541-024-00883-3. NPJ Vaccines. 2024. PMID: 38822003 Free PMC article.
-
Use of Adjuvanted Quadrivalent Influenza Vaccine in Older-Age Adults: A Systematic Review of Economic Evidence.Vaccines (Basel). 2024 May 10;12(5):523. doi: 10.3390/vaccines12050523. Vaccines (Basel). 2024. PMID: 38793774 Free PMC article. Review.
-
Pharmacy-Based Influenza Vaccination: A Study of Patient Acceptance in Romania.Risk Manag Healthc Policy. 2024 Apr 24;17:1005-1013. doi: 10.2147/RMHP.S459369. eCollection 2024. Risk Manag Healthc Policy. 2024. PMID: 38690537 Free PMC article.
-
Specific and Nonspecific Effects of Influenza Vaccines.Vaccines (Basel). 2024 Apr 5;12(4):384. doi: 10.3390/vaccines12040384. Vaccines (Basel). 2024. PMID: 38675766 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical